Product Description
Reference Standards &Impurity
AI Product Description
*The following content is generated by AI and is for reference only.
Glibenclamide, also known as glyburide, is a second-generation sulfonylurea oral hypoglycemic agent widely utilized in the management of type 2 diabetes mellitus. Chemically characterized by the molecular formula C23H28ClN3O5S and assigned the CAS number 10238-21-4, this compound functions primarily by stimulating insulin secretion from pancreatic beta cells. Its mechanism involves binding to specific ATP-sensitive potassium channels on the cell membrane, leading to channel closure, cellular depolarization, calcium influx, and subsequent release of stored insulin. This action effectively lowers blood glucose levels, making it a cornerstone therapy for patients whose condition cannot be controlled through diet and exercise alone.
The drug is available in various formulations, including tablets of different strengths (typically 1.25 mg, 2.5 mg, and 5 mg), allowing for flexible dosing regimens tailored to individual patient needs. Due to its potent efficacy, glibenclamide is often prescribed when other first-line agents like metformin are insufficient or contraindicated. However, its use requires careful monitoring due to the risk of hypoglycemia, particularly in elderly patients or those with renal impairment. The pharmacokinetic profile features a relatively long duration of action, which supports once-daily or twice-daily administration schedules, thereby improving patient compliance compared to shorter-acting alternatives.
Beyond its primary indication, research continues to explore potential secondary benefits, though clinical focus remains strictly on glycemic control within established safety guidelines. It is manufactured by numerous pharmaceutical companies globally under various brand names such as Daonil, Euglucon, and Glynase. While generally well-tolerated, common side effects may include weight gain, gastrointestinal disturbances, and rare instances of skin rashes or hematological abnormalities. Physicians must consider drug interactions, especially with non-steroidal anti-inflammatory drugs and certain antibiotics, which can alter glibenclamide metabolism. As a critical component of modern antidiabetic therapy, glibenclamide remains an essential tool in the global effort to manage the growing prevalence of diabetes, balancing effective glucose reduction with the imperative of patient safety and long-term metabolic health.